Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
| Author | |
|---|---|
| Abstract |
:
We assessed the efficacy and safety of once-daily eslicarbazepine acetate in comparison with twice-daily (BID) controlled-release carbamazepine (carbamazepine-CR) monotherapy in newly diagnosed focal epilepsy patients. |
| Year of Publication |
:
2018
|
| Journal |
:
Epilepsia
|
| Date Published |
:
2018
|
| ISSN Number |
:
0013-9580
|
| URL |
:
http://dx.doi.org/10.1111/epi.13993
|
| DOI |
:
10.1111/epi.13993
|
| Short Title |
:
Epilepsia
|
| Download citation |
